Table 1

Demographic characteristics and clinical outcomes at baseline and change scores at 6-month follow-up

Baseline6-month follow-upRelative changeEffect sizeP value
nMeanSDnMeanSD(%)
Age16761.210.7
Disease duration16610.54.9
Sex (female/male) (%)167(105/62)(62.9/37.1%)
Levodopa challenge test response (%)1640.50.2
PDQ-8 Summary Index16733.815.116125.716−24.00.52 <0.001
NMSS total16662.436.916242.427.7−32.10.61 <0.001
Hoehn and Yahr1632.40.91592.20.7−8.30.25 0.001
UPDRS-III1672612.91582010.1−23.10.52 <0.001
SCOPA-motor ADL1607.33.21555.43.1−26.00.60 <0.001
SCOPA-motor complications1605.12.91542.72.6−47.10.87 <0.001
LEDD1661107.1515.8162566.0346.7−48.91.23 <0.001
  • We analysed outcome changes from baseline to 6-month follow-up with Wilcoxon signed-rank tests and used Benjamini-Hochberg correction for multiple comparisons due to the use of multiple tests (seven clinical outcomes). We calculate relative change from baseline to follow-up ((mean testbaseline–mean testfollow-up)/mean testbaseline×100) and quantified effect size with Cohen’s d.

  • Bold font highlights significant results.

  • ADL, activities of daily living; LEDD, levodopa equivalent daily dose; NMSS, Non-motor Symptom Scale; PDQ-8, Parkinson’s Disease Questionnaire-8; SCOPA, Scales for Outcomes in Parkinson’s Disease; UPDRS-III, Unified Parkinson’s Disease Rating Scale-Motor Examination.